US Oncology Reports Fourth Quarter and Fiscal Year 20...((2761) (5051) Proceeds from iss...)

Proceeds from issuance of common stock - 99,274

Proceeds from issuance of preferred stock - 50,726

Payment of dividends on preferred stock (25,000) -

Payment of dividends on common stock (323,580) -

Debt financing costs (1,575) (714)

Offering costs - (608)

Distributions to minority interests (1,925) (2,320)

Contributions from minority interests - 1,015

Proceeds from exercise of options 521 337

Net cash provided by (used in) financing activities (204,018) 246,181

Increase (decrease) in cash and equivalents (132,511) 155,930

Cash and equivalents:

Beginning of period 281,768 125,838

End of period $149,257 $281,768

US ONCOLOGY HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands)

December 31, December 31,

2007 2006

ASSETS

Current assets:

Cash and equivalents $149,257 $281,768

Accounts receivable 318,976 341,306

Other receivables 120,285 105,544

Prepaid expenses and other current assets 26,544 21,139

Inventories 82,822 78,381

Deferred income taxes 7,428 4,268

Due from affiliates
'/>"/>